T. Koutsoukos

发表

Assessment of futility in clinical trials

Steven Snapinn, Mon-Gy Chen, Qi Jiang, 2006, Pharmaceutical statistics.

Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.

D. Fisher, S. Horwitz, N. Bartlett, 2012, Blood.

Retrospective chart review of urinary glycosaminoglycan excretion and long-term clinical outcomes of enzyme replacement therapy in patients with mucopolysaccharidoses.

D. Marsden, K. Tylee, E. Kakkis, 2020, Molecular genetics and metabolism.

Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.

B. Coiffier, C. Haioun, S. Horwitz, 2012, Clinical lymphoma, myeloma & leukemia.

Aceneuramic Acid Extended Release Administration Maintains Upper Limb Muscle Strength in a 48-week Study of Subjects with GNE Myopathy: Results from a Phase 2, Randomized, Controlled Study

A. Pestronk, P. Shieh, Y. Caraco, 2016, Journal of neuromuscular diseases.

Results from a 3-year Non-interventional, Observational Disease Monitoring Program in Adults with GNE Myopathy

M. Tarnopolsky, H. Lochmüller, R. Horvath, 2021, Journal of neuromuscular diseases.

A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy

M. Tarnopolsky, H. Lochmüller, M. Mirabella, 2019, Neurology.

Pralatrexate (PDX) IS Active in Cutaneous T-Cell Lymphoma: Preliminary Results of a Multi-Center Dose-Finding Trial.

S. Horwitz, O. O’Connor, M. Duvic, 2008 .

A randomized, double‐blind trial of triheptanoin for drug‐resistant epilepsy in glucose transporter 1 deficiency syndrome

I. Scheffer, P. Striano, I. Miller, 2022, Epilepsia.

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy

C. Azzoli, K. Kelly, J. R. Pereira, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.

D. Fisher, S. Horwitz, N. Bartlett, 2010 .

Pralatrexate Is An Effective Treatment for Heavily Pretreated Patients with Relapsed/Refractory Transformed Mycosis Fungoides (tMF)

K. Savage, B. Coiffier, S. Horwitz, 2010 .

Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy

C. Azzoli, K. Kelly, J. R. Pereira, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.